Morgan Stanley
BIAF icon

Morgan Stanley’s bioAffinity Technologies BIAF Stock Holding History

Morgan Stanley’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Hold
3
– – ﹤0.01% 8381
2026
Q1 		$11 Hold
3
– – ﹤0.01% 8204
2025
Q4 		$4 Hold
3
– – ﹤0.01% 8161
2025
Q3 		$9 Hold
3
– – ﹤0.01% 8102
2025
Q2 		$29 Sell
3
-7
-70% -$80 ﹤0.01% 7927
2025
Q1 		$78 Sell
10
-7
-41% -$128 ﹤0.01% 7615
2024
Q4 		$455 Sell
17
-148
-90% -$5.96K ﹤0.01% 7354
2024
Q3 		$10.3K Buy
165
+132
+400% +$7.91K ﹤0.01% 6712
2024
Q2 		$2.16K Buy
+33
New +$2.29K ﹤0.01% 7053
2023
Q1 		– Hold
0
– -$5 – 7716
2022
Q4 		– Hold
0
– – – 7830

Other funds holding BIAF

JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley's BIAF Position: Q2 2026 in Review

Morgan Stanley held its bioAffinity Technologies (BIAF) position steady in Q2 2026 at 3 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #8381.

Morgan Stanley first reported a position in BIAF in Q2 2024 and has held it in 9 quarters since. The position peaked at $10.3K in Q3 2024. 14 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

  • Morgan Stanley held 3 shares of bioAffinity Technologies worth $2 as of Q2 2026.
  • Morgan Stanley left its bioAffinity Technologies share count unchanged in Q2 2026.
  • bioAffinity Technologies made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8381 holding.
  • Morgan Stanley first reported a position in bioAffinity Technologies in Q2 2024 and has held it in 9 quarters since.
  • Morgan Stanley's bioAffinity Technologies position peaked at $10.3K in Q3 2024.
  • 14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.